W is substituted or unsubstituted aryl;

X is S;

Y is $N(R^5)$;

Z is N;

R^1 and R^2 are independently selected from H, halogen, CN, CO_2R', CONR'R", $(C_1\text{-}C_8)$alkyl, heteroalkyl, aryl, heteroaryl and $N(R^6)(R^7)$, OR^9, wherein R' and R" are independently selected from H, $(C_1\text{-}C_8)$alkyl and aryl, and when R' and R" are attached to nitrogen atom, they may be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring;

R^5 is selected from H, $(C_1\text{-}C_8)$alkyl, heteroalkyl, aryl and heteroaryl;

R^6 and R^7 are independently selected from H, $(C_1\text{-}C_8)$alkyl, heteroalkyl, aryl and heteroaryl; and

R^9 is selected from $(C_1\text{-}C_8)$alkyl, heteroalkyl and haloalkyl;

and wherein R^2 is other than H when W is unsubstituted phenyl, Y is NH and R^1 is $(C_1\text{-}C_8)$alkyl; and R^1 is other than phenyl, when W is phenyl or unsubstituted naphthyl and Y is NH.

86. (new) A compound of claim 85, wherein W is substituted or unsubstituted phenyl or naphthyl.

87. (new) A compound of claim 85, wherein R^1 and R^2 are each independently selected from H and $(C_1\text{-}C_8)$alkyl.

88. (new) A compound of claim 85, wherein W is substituted or unsubstituted naphthyl, and R^1 and R^2 are each independently selected from H and $(C_1\text{-}C_8)$alkyl.

89. (new) A compound of claim 85, wherein W is substituted or unsubstituted phenyl, and R^1 and R^2 are each independently selected from H and (C_1-C_8)alkyl.

90. (new) A compound of claim 85, said compound being selected from the group consisting of:


12


2


4


9


10




1


13


5


6


8


15

and


18

91. (new) A compound of claim 85, said compound being selected from the group consisting of:



4

and



1

92. (new) A compound of claim 85, wherein W is substituted phenyl or substituted or unsubstituted naphthyl, and R^1 and R^2 are independently selected from the group consisting of H and $(C_1\text{-}C_8)$alkyl.

93. (new) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula (**I**):



I

or a pharmaceutically acceptable salt thereof, wherein

W is substituted or unsubstituted aryl;

X is S;

Y is $N(R^5)$;

Z is N;

R^1 and R^2 are independently selected from H, halogen, CN, CO_2R', CONR'R", $(C_1\text{-}C_8)$alkyl, heteroalkyl, aryl, heteroaryl and $N(R^6)(R^7)$, OR^9, wherein R' and R" are independently selected from H, $(C_1\text{-}C_8)$alkyl and aryl, and when R' and R" are attached to nitrogen atom, they may be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring;

R^5 is selected from H, $(C_1\text{-}C_8)$alkyl, heteroalkyl, aryl and heteroaryl;

R^6 and R^7 are independently selected from H, $(C_1\text{-}C_8)$alkyl, heteroalkyl, aryl and heteroaryl; and

R^9 is selected from $(C_1\text{-}C_8)$alkyl, heteroalkyl and haloalkyl;

and wherein R^2 is other than H when W is unsubstituted phenyl, Y is NH and R^1 is $(C_1\text{-}C_8)$alkyl; and R^1 is other than phenyl, when W is phenyl or unsubstituted naphthyl and Y is NH.

94. (new) A method for treating a CCR4-mediated condition in a subject, said method comprising administering to a subject in need of such treatment an effective amount of a compound of of formula (**I**):



I

or a pharmaceutically acceptable salt thereof, wherein

W is substituted or unsubstituted aryl;

X is S;

Y is $N(R^5)$;

Z is N;

R^1 and R^2 are independently selected from H, halogen, CN, CO_2R', CONR'R", $(C_1\text{-}C_8)$alkyl, heteroalkyl, aryl, heteroaryl and $N(R^6)(R^7)$, OR^9, wherein R' and R" are independently selected from H, $(C_1\text{-}C_8)$alkyl and aryl, and when R' and R" are attached to nitrogen atom, they may be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring;

R^5 is selected from H, $(C_1\text{-}C_8)$alkyl, heteroalkyl, aryl and heteroaryl;

R^6 and R^7 are independently selected from H, $(C_1\text{-}C_8)$alkyl, heteroalkyl, aryl and heteroaryl; and

R^9 is selected from $(C_1\text{-}C_8)$alkyl, heteroalkyl and haloalkyl;

and wherein R^2 is other than H when W is unsubstituted phenyl, Y is NH and R^1 is $(C_1\text{-}C_8)$alkyl; and R^1 is other than phenyl, when W is phenyl or unsubstituted naphthyl and Y is NH.

95. (new) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected from the group consisting of:





12



2



4



9



10





1



13



5



18



8



15

and



6

96. (new) A pharmaceutical composition of claim 95, wherein said compound is selected from the group consisting of:



4 **1**

97. (new) A method for treating a CCR4-mediated condition in a subject, said method comprising administering to a subject in need of such treatment an effective amount of a compound selected from the group consisting of:



22 **23** **24** **25**



26 **27** **28** **21**



12 ,



2 ,



4 ,



9 ,



10 ,



,



1 ,



13 ,



5 ,



18



8 ,



15

and



6